Zydus Lifesciences Gets Strong ESG Score of 66 from CRISIL Ratings
Zydus Lifesciences Limited's ESG score has been upgraded to 66 by CRISIL Ratings, indicating a 'strong' performance. The previous score was 61. The assessment is based on data from the financial year 2025-2026.
While a positive development, an ESG rating upgrade typically has a low direct impact on the company's immediate financial performance or stock price.
The company received an improved ESG score, which is categorized as 'strong', indicating a positive development in its sustainability and governance practices.
Zydus Lifesciences Limited has received an enhanced Environment, Social, and Governance (ESG) score of 66 from CRISIL Ratings Limited. This updated score reflects an improvement from the previous score of 61.
The ESG score was assigned based on data pertaining to the financial year 2025-2026, as detailed in CRISIL's report dated August 24, 2026.
According to the CRISIL Ratings framework, an ESG score between 61 and 70 is categorized as 'strong'. This disclosure is made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with the SEBI Master Circular dated January 30, 2026.
What to do with a filing like this
Zydus Lifesciences Limited filed this with the NSE as a statutory disclosure, categorised under esg reports. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Zydus Lifesciences Limited. Read the original for the full detail.